From WikiProjectMed
Jump to navigation Jump to search

Natalizumab 4IRZ.png
Natalizumab Fab fragment bound to the headpiece of an α4-integrin. From PDB 4IRZ​.
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetalpha-4 integrin
Trade namesTysabri, Antegren, others
Other namesAN100226M
Clinical data
Main usesMultiple sclerosis (MS), Crohn's disease (CD)[1]
Side effectsUrinary tract infection, throat inflammation, headache, dizziness, nausea, joint pain, tiredness[2]
  • AU: C[3]
  • US: N (Not classified yet)[3]
Routes of
Intravenous infusion
Typical dose300 mg q 4 weeks[1]
External links
License data
Legal status
  • UK: POM (Prescription only) [4]
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Elimination half-life11 ± 4 days
Chemical and physical data
Molar mass149 kg/mol

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis (MS) and Crohn's disease (CD).[1] For MS it is used for clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[1] For CD it is used when other treatments are not effective.[1] It is given by gradual injection into a vein every 4 weeks.[2]

Common side effects include urinary tract infection, throat inflammation, headache, dizziness, nausea, joint pain and tiredness.[2] Other side effects may include progressive multifocal leukoencephalopathy (PML), herpes encephalitis, liver problems, anaphylaxis, low platelets, and infection.[1] It is a monoclonal antibody which attaches to a protein called α4β1 integrin on white blood cells, decreasing inflammation.[2]

Natalizumab was approved for medical use in the United States in 2004 and Europe in 2006.[5][2] In the United Kingdom it costs the NHS about £1,100 per dose as of 2021.[6] In the United States this amount costs about 7,800 USD.[7]

Medical uses

Natalizumab is FDA-approved for the treatment of multiple sclerosis; in the US it is also used for Crohn's disease.[8]

Natalizumab offers a limited improvement in efficacy compared to other treatments for MS, but due to the lack of information about long-term use, as well as potentially fatal adverse events, reservations have been expressed over the use of the drug outside of comparative research with existing medications.[9][10][11] Natalizumab is used as a monotherapy.[12]

In the EU, natalizumab is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:

  • People with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT), or[2]
  • People with rapidly evolving severe relapsing remitting multiple sclerosis defined by two or more disabling relapses in one year, and with one or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.[2]


It is generally given as 300 mg every 4 weeks.[1]

Side effects

Bruising of the left calf on 11th day after natalizumab infusion.

Common adverse effects include fatigue and allergic reactions with a low risk of anaphylaxis,[13] headache, nausea, colds and exacerbation of Crohn's disease in a minority of patients with the condition.[medical citation needed] Adolescents with Crohn's disease experience headache, fever and exacerbation of Crohn's disease.[medical citation needed] Natalizumab is contraindicated for people with known hypersensitivity to the drug or its components and in patients with a history of PML (see interactions).

Postmarketing surveillance in early 2008 revealed that 0.1% of people taking natalizumab experience clinically significant liver injury, leading to the FDA, EMEA and manufacturers recommending that the medication be discontinued in people with jaundice or other evidence of significant liver damage.[14][15][16] This rate is comparable to other immune-suppressing drugs.[17] Evidence of hepatotoxicity in the form of elevated blood levels of bilirubin and liver enzymes can appear as soon as six days after an initial dose; reactions are unpredictable and may appear even if the patient does not react to previous treatment.[18] Such signs reoccur upon rechallenge in some patients, indicating that damage is not coincidental.[18] In the absence of any blockage these liver function tests are predictors of severe liver injury with possible sequelae of liver transplantation or death.[18]

Natalizumab has also been linked to melanoma, though the association is unclear.[19] The long-term effects of the drug are unknown[20] and concern has been expressed over the risks of infection and cancer.[9]

Natalizumab can increase the risk of infections, including the brain infection PML.[2] PML is a very serious condition that may result in severe disability or death.[2] The risk of PML increases the longer a person has been receiving natalizumab, especially in people treated for more than two years.[2] The risk is also higher for people who used medicines that suppress the immune system before starting natalizumab, or if the person has antibodies against the virus that causes PML.[2]

About 6% of the people in studies developed long-lasting antibodies against natalizumab, which reduced the medicine's effectiveness.[2]

Progressive multifocal leukoencephalopathy

Progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus, and that occurs only in ppeople who are immunocompromised, has affected an estimated 212 patients as of 2012, or 2.1 in every 1,000 using natalizumab.[21] It was first observed in seven people who received natalizumab in late 2008;[22] three cases were noted in clinical trials in 2006[23] leading to the drug being temporarily pulled from the market; two cases were reported to the FDA in August 2008;[24] and two cases were announced in December 2008.[22] By 21 January 2010 the FDA noted a total of 31 confirmed cases of PML, with the chance of developing the infection increasing as the number of infusions received by a patient increased. Because of this association, the drug label and package insert accompanying the drug will be updated to include this information.[25] As of 29 February 2012, there were 212 confirmed cases of PML among 99,571 patients treated with natalizumab (2.1 cases per 1000 patients). All 54 patients with PML for whom samples were available before the diagnosis were positive for anti–JC virus antibodies. When the risk of PML was evaluated according to three risk factors, it was lowest among the patients who had used natalizumab for the shortest periods, those who had used few if any immunosuppressant drugs to treat MS in the past, and lastly who were negative for anti–JC virus antibodies. The incidence of PML in the low risk group was estimated to be 0.09 cases, or less, per 1000 patients. Patients who had taken natalizumab for longer, from 25 to 48 months, who were positive for anti–JC virus antibodies, had taken immunosuppressants before the initiation of natalizumab therapy had the highest risk of developing PML. Their risk is fully 123 times higher than the low risk group. (incidence, 11.1 cases per 1000 patients [95% CI, 8.3 to 14.5]).[21] While none of them had taken the drug in combination with other disease-modifying treatments, previous use of MS treatments increases the risk of PML between 3 and 4-fold.[26] In 2016, EMA recommended all people taking natalizumab should undergo full MRI scans at least once a year due to concerns of progressive multifocal leukoencephalopathy (PML). In addition, more frequent MRI scans (e.g. every 3 to 6 months) should be performed using simplified protocols should be considered for those at higher risk of PML.[27]


Natalizumab appears to interact with other immune-modulating drugs to increase the risk of progressive multifocal leukoencephalopathy (PML), an often-fatal opportunistic infection caused by the JC virus. In 2005, two people taking natalizumab in combination with interferon beta-1a developed PML. One died, and the other recovered with disabling sequelae.[28][29] A third fatal case initially attributed to an astrocytoma was reported in a patient being treated for Crohn's disease.[30] Though the patient was being treated with natalizumab in combination with azathioprine, corticosteroids and infliximab, indications of PML infection appeared only after natalizumab monotherapy was re-introduced.[30] No deaths from progressive multifocal leukoencephalopathy have been linked to natalizumab when it was not combined with other immune-modulating drugs[31] and other rates of opportunistic infections are not increased in patients taking natalizumab[32] possibly due to the drug's mechanism of action.[33] Other than a prior history of PML, there is no known method to identify patients at risk of developing PML.[34] Natalizumab's label indicates that it is contraindicated for immunosuppressed individuals or those with a history of PML.[35] Due to the uncertain risk of PML, natalizumab is only available through a restricted distribution program.[35] By 21 January 2010 the United States Food and Drug Administration reported a total of 31 confirmed cases of PML associated with natalizumab.[36]

Though the small number of cases precludes conclusion on the ability of natalizumab alone to induce PML, its black box warning states that the drug has only been linked to PML when combined with other immune-modulating drugs and natalizumab is contraindicated for use with other immunomodulators.[35] Corticosteroids may produce immunosuppression, and the Tysabri prescribing information recommends that people taking corticosteroids for the treatment of Crohn's disease have their doses reduced before starting natalizumab treatment.[35] The risk of developing PML was later estimated to be 1 in 1,000 (0.1%) over 18 months[10][32][37] though the longer term risks of PML are unknown.[10]

Mechanism of action

Structure of a generic antibody

Natalizumab is a humanized monoclonal antibody against alpha-4 (α4) integrin, the first drug developed in the class of selective adhesion molecule inhibitors. α4-integrin is required for white blood cells to move into organs, and natalizumab's mechanism of action is believed to be the prevention of immune cells from crossing blood vessel walls to reach affected organs.[38]

Multiple sclerosis

The symptom-causing lesions of MS are believed to be caused when inflammatory cells such as T-lymphocytes pass through the blood–brain barrier through interaction with receptors on the endothelial cells. Natalizumab appears to reduce the transmission of immune cells into the central nervous system by interfering with the α4β1-integrin receptor molecules on the surfaces of cells. The effect appears to occur on endothelial cells expressing the VCAM-1 gene, and in parenchymal cells expressing the osteopontin gene. In animals used to model MS and test therapies, repeated administration of natalizumab reduced migration of leukocytes into the brain's parenchyma, and also reduced lesioning, though it is uncertain if this is clinically significant for humans.[35]

Individuals with MS dosed with natalizumab demonstrated increased CD34-expressing cells, with research suggesting a peak in expression after 72 hours.[39]

Crohn's disease

The interaction of the α4β7 integrin and the addressin (also known as MADCAM1) endothelial cell receptor is believed to contribute to the chronic bowel inflammation that causes Crohn's disease. Addressin is primarily expressed in the endothelium of venules in the small intestine and are critical in guiding T-lymphocytes to lymphatic tissues in Peyer's patches. In CD patients, sites of active inflammation of the bowel in CD patients have increased expression of addressin, suggesting a connection between the inflammation and the receptor. Natalizumab may block interaction between the α4β7 integrin and addressin at sites of inflammation. Animal models have found higher levels of VCAM-1 expression in mice with irritable bowel syndrome and the VCAM-1 gene may also play a part in CD but its role is not yet clear.[35]


Biogen Idec announced the initiation of the first clinical trial of natalizumab as a potential cancer treatment as of 5 September 2008.[40]

It was withdrawn from the market by its manufacturer after it was linked with three cases of the neurological condition progressive multifocal leukoencephalopathy (PML) when administered in combination with interferon beta-1a, another immunosuppressive drug. After a review of safety information and no further deaths, the drug was returned to the US market in 2006 under a special prescription program. As of June 2009, ten cases of PML were known. However, twenty-four cases of PML had been reported since its reintroduction by October 2009, showing a sharp rise in the number of fatalities and prompting a review of the chemical for human use by the European Medicines Agency.[41] By 2010, 31 cases of PML were attributed to natalizumab while by 2018 this had risen to 757 cases.[36][42] The FDA did not withdraw the drug from the market as they consider the benefits outweigh the risks.[43] In the European Union, it has been approved only for multiple sclerosis and only by itself as the initial cases of PML, and later the fatalities, were said by the manufacturers to be linked to the use of previous medicines by the person.[44]

Legal status

Natalizumab was originally approved for treatment of multiple sclerosis in 2004, through the FDA's accelerated Fast Track program, due to the drug's efficacy in one-year clinical trials. In February 2005, four months after its approval, natalizumab was withdrawn voluntarily by the manufacturer after two cases of progressive multifocal leukoencephalopathy. Groups representing individuals with MS lobbied to have the drug returned to the US market[45] and in June, 2006, after recommendation by an advisory committee and a review of two years of safety and efficacy data, the FDA re-approved natalizumab for patients with all relapsing forms of MS (relapse-remitting, secondary-progressive, and progressive-relapsing) as a first-line or second-line therapy.[46][47] Patients taking natalizumab must enter into a registry for monitoring.[45] Natalizumab is the only drug after alosetron withdrawn for safety reasons that returned to the US market.[citation needed]

In April 2006, the Committee for Medicinal Products for Human Use recommended authorizing natalizumab to treat relapsing-remitting MS, and natalizumab was approved for medical use in the European Union in June 2006.[8][2]

Health Canada added natalizumab to Schedule F of the Food and Drug Regulations on 3 April 2008, as a prescription drug requiring oversight from a physician.[48]

In 2007, the EMA rejected the application to market natalizumab for Crohn's disease due to concerns over its risk/benefit ratio.[49] In January 2008, the FDA approved it for the induction of remission and maintenance of remission for moderate to severe Crohn's disease.[50]


  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Tysabri- natalizumab injection". DailyMed. 12 August 2019. Archived from the original on 27 March 2020. Retrieved 4 May 2020.
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 "Tysabri EPAR". European Medicines Agency (EMA). Archived from the original on 6 August 2020. Retrieved 4 May 2020. Text was copied from this source, which is © EMA [1995-2020]. Reuse is authorised, provided the source is acknowledged.
  3. 3.0 3.1 "Natalizumab (Tysabri) Use During Pregnancy". 24 September 2019. Archived from the original on 23 November 2020. Retrieved 4 May 2020.
  4. "Tysabri 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 14 November 2019. Archived from the original on 22 October 2020. Retrieved 4 May 2020.
  5. "Natalizumab Monograph for Professionals". Archived from the original on 6 February 2017. Retrieved 12 November 2021.
  6. BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 905. ISBN 978-0857114105.
  7. "Tysabri Prices, Coupons & Patient Assistance Programs". Archived from the original on 24 January 2021. Retrieved 12 November 2021.
  8. 8.0 8.1 "European Medicines Agency: Committee for Medicinal Products for Human Use 24–27 April 2006" (PDF) (Press release). European Medicines Agency (EMA). 28 April 2006. Archived (PDF) from the original on 10 July 2007. Retrieved 2 April 2008.
  9. 9.0 9.1 "Natalizumab: new drug. Multiple sclerosis: risky market approval". Prescrire Int. 17 (93): 7–10. 2008. PMID 18354844.
  10. 10.0 10.1 10.2 Hutchinson M (2007). "Natalizumab: A new treatment for relapsing remitting multiple sclerosis". Ther Clin Risk Manag. 3 (2): 259–268. doi:10.2147/tcrm.2007.3.2.259. PMC 1936307. PMID 18360634.
  11. Pucci, Eugenio; Giuliani, Giorgio; Solari, Alessandra; Simi, Silvana; Minozzi, Silvia; Di Pietrantonj, Carlo; Galea, Ian (5 October 2011). "Natalizumab for relapsing remitting multiple sclerosis". The Cochrane Database of Systematic Reviews (10): CD007621. doi:10.1002/14651858.CD007621.pub2. ISSN 1469-493X. PMID 21975773.
  12. "Annex: Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the member states" (PDF). European Medicines Agency. Archived from the original (PDF) on 20 August 2007. Retrieved 9 March 2008.
  13. Horga A, Horga de la Parte JF (2007). "[Natalizumab in the treatment of multiple sclerosis]". Rev Neurol (in español). 45 (5): 293–303. PMID 17876741.
  14. "FDA MedWatch - 2008 Safety Information Alerts". Food and Drug Administration. 28 February 2008. Archived from the original on 25 May 2009. Retrieved 5 April 2008.
  15. "EMEA concludes new advice to doctors and patients for Tysabri (natalizumab) needed" (PDF). European Medicines Agency. 20 March 2008. Retrieved 5 April 2008.[dead link]
  16. "Questions and answers on Tysabri and liver injury" (PDF). European Medicines Agency. 20 March 2008. Retrieved 14 April 2008.{{cite web}}: CS1 maint: url-status (link) ; lay-summary Archived 11 June 2008 at the Wayback Machine, second summary Archived 5 December 2008 at the Wayback Machine
  17. Kenneth Gross, M.D. (3 March 2008). "Multiple Sclerosis - Natalizumab (Tysabri) Can Rarely Cause Liver Problems". Archived from the original on 7 November 2016. Retrieved 5 April 2008.
  18. 18.0 18.1 18.2 Panzara, M; Francis V (1 February 2008). "Important safety information: Dear Healthcare Practitioner letter" (PDF). Biogen Idec and Élan. Archived (PDF) from the original on 12 May 2009. Retrieved 11 April 2008.; lay summary Archived 11 June 2008 at the Wayback Machine
  19. Mullen JT, Vartanian TK, Atkins MB (2008). "Melanoma complicating treatment with natalizumab for multiple sclerosis". N. Engl. J. Med. 358 (6): 647–8. doi:10.1056/NEJMc0706103. PMID 18256405.
  20. van Bronswijk H, Dubois EA, van Gerven JM, Cohen AF (2008). "[New drugs; natalizumab]". Ned Tijdschr Geneeskd (in Nederlands). 152 (9): 499–500. PMID 18389881.
  21. 21.0 21.1 Bloomgren, Gary; Richman, Sandra; Hotermans, Christophe; Subramanyam, Meena; Goelz, Susan; Natarajan, Amy; Lee, Sophia; Plavina, Tatiana; Scanlon, James V.; Sandrock, Alfred; Bozic, Carmen (2012). "Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy". New England Journal of Medicine. 366 (20): 1870–1880. doi:10.1056/NEJMoa1107829. ISSN 0028-4793. PMID 22591293.
  22. 22.0 22.1 Greene, Robert T. (15 December 2008). "Biogen, Elan Report Brain Illness in Tysabri Patient". Archived from the original on 28 October 2021. Retrieved 21 December 2008.
  23. Van Assche G, Van Ranst M, Sciot R, et al. (July 2005). "Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease". N. Engl. J. Med. 353 (4): 362–8. doi:10.1056/NEJMoa051586. PMID 15947080.
  24. U.S. Food and Drug Administration (August 2008). "Natalizumab Injection for Intraveneous {{sic}} Use (marketed as Tysabri)". Archived from the original on 19 December 2008. Retrieved 22 December 2008.
  25. "FDA Drug Safety Communication: Risk of Progressive Multifocal Leukoencephalopathy (PML) with the use of Tysabri (natalizumab)". FDA. 2 May 2010. Archived from the original on 24 April 2019. Retrieved 31 August 2010.
  26. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J (August 2011). "Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring". Lancet Neurology. 10 (8): 745–58. doi:10.1016/S1474-4422(11)70149-1. PMID 21777829. S2CID 15639613.
  27. "EMA confirms recommendations to minimise risk of brain infection PML with Tysabri". European Medicines Agency. 25 April 2016. Archived from the original on 23 January 2021. Retrieved 27 August 2021.
  28. Kleinschmidt-DeMasters BK, Tyler KL (2005). "Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis". N. Engl. J. Med. 353 (4): 369–74. doi:10.1056/NEJMoa051782. PMID 15947079.
  29. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005). "Progressive multifocal leukoencephalopathy in a patient treated with natalizumab". N. Engl. J. Med. 353 (4): 375–81. doi:10.1056/NEJMoa051847. PMID 15947078.
  30. 30.0 30.1 Van Assche G, Van Ranst M, Sciot R, et al. (2005). "Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease". N. Engl. J. Med. 353 (4): 362–8. doi:10.1056/NEJMoa051586. PMID 15947080.
  31. Yousry TA, Major EO, Ryschkewitsch C; et al. (2006). "Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy". N. Engl. J. Med. 354 (9): 924–33. doi:10.1056/NEJMoa054693. PMC 1934511. PMID 16510746.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  32. 32.0 32.1 Berger JR (2006). "Natalizumab". Drugs Today. 42 (10): 639–55. doi:10.1358/dot.2006.42.10.1042190. PMID 17136224.
  33. Ransohoff RM (2007). ""Thinking without thinking" about natalizumab and PML". J. Neurol. Sci. 259 (1–2): 50–2. doi:10.1016/j.jns.2006.04.011. PMID 17521672. S2CID 28808262.
  34. Aksamit AJ (2006). "Review of progressive multifocal leukoencephalopathy and natalizumab". Neurologist. 12 (6): 293–8. doi:10.1097/01.nrl.0000250948.04681.96. PMID 17122725. S2CID 25003597.
  35. 35.0 35.1 35.2 35.3 35.4 35.5 "Final TYSABRI PI" (PDF). Archived from the original (PDF) on 22 August 2007. Retrieved 13 March 2008.
  36. 36.0 36.1 Jeffrey, S (5 February 2010). "PML Risk Increases With Repeated Natalizumab Infusions: FDA". Medscape. Archived from the original on 26 January 2012. Retrieved 31 August 2010.
  37. Kappos L, Bates D, Hartung HP, et al. (2007). "Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring". Lancet Neurol. 6 (5): 431–41. doi:10.1016/S1474-4422(07)70078-9. PMID 17434098. S2CID 18131415.
  38. Rice GP, Hartung HP, Calabresi PA (2005). "Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale". Neurology. 64 (8): 1336–42. doi:10.1212/01.WNL.0000158329.30470.D0. PMID 15851719. S2CID 39916466.
  39. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R (2008). "The monoclonal anti-VLA4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans". Blood. 111 (7): 3893–5. doi:10.1182/blood-2007-10-120329. PMID 18235044.
  40. "Biogen Idec testing Tysabri as a cancer treatment". The Boston Globe. 5 September 2008. Archived from the original on 29 October 2013. Retrieved 5 September 2008.
  41. "Meeting highlights from the Committee for Medicinal Products for Human Use" (PDF). European Medicines Agency. 22 October 2009. Archived from the original (PDF) on 27 December 2009. Retrieved 31 August 2010.
  42. "Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time". ECTRIMS. 10 October 2018. Archived from the original on 28 October 2021. Retrieved 18 July 2019.
  43. Hitti, M (1 August 2008). "MS Drug Tysabri Tied to Brain Infection". WebMD. Archived from the original on 20 November 2018. Retrieved 31 August 2010.
  44. Staton, Tracy (26 October 2009). "Tysabri safety falls under EMEA scrutiny". Fierce Pharma. Archived from the original on 23 January 2021. Retrieved 27 August 2021.
  45. 45.0 45.1 Pollack, A (9 March 2006). "F.D.A. Panel Recommends M.S. Drug Despite Lethal Risk". The New York Times. Archived from the original on 11 January 2016. Retrieved 13 March 2008.
  46. "Errata to FDA Background document for the Tysabri (natalizumab) Advisory Committee on July 31, 2007" (PDF). Food and Drug Administration. 20 July 2007. Archived (PDF) from the original on 17 May 2017. Retrieved 9 March 2008.
  47. Fiore D (2007). "Multiple sclerosis and natalizumab". Am J Ther. 14 (6): 555–60. doi:10.1097/MJT.0b013e31804bfa6a. PMID 18090880. S2CID 22339176.
  48. "SOR/2008-101: Food and Drug Act; Regulations Amending the Food and Drug Regulations (1528—Schedule F)" (PDF). Canada Gazette Part I. 142 (8): 649. 16 April 2008. Archived (PDF) from the original on 18 August 2011. Retrieved 27 August 2021.
  49. "Refusal CHMP assessment report for natalizumab" (PDF). European Medicines Agency. 15 November 2007. Retrieved 2 April 2008.[permanent dead link] "lay-summary" (PDF). Archived from the original (PDF) on 18 July 2009. Retrieved 14 March 2022. (78.5 KB)
  50. "FDA Approves Tysabri to Treat Moderate-to-Severe Crohn's Disease". Food and Drug Administration. 14 January 2008. Archived from the original on 23 May 2009. Retrieved 9 March 2008.

External links

External sites: